
Invivyd Investor Relations Material
Latest events

Q1 2025
Invivyd
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Invivyd Inc
Access all reports
Invivyd Inc., a clinical-stage biopharmaceutical company, is focused to the discovery, development, and commercialization of antibody-based solutions targeting infectious diseases, with a primary focus on the United States. The company's mission centers on delivering antibody-based therapies to protect vulnerable populations against circulating viral threats, such as SARS-CoV-2, leveraging advanced antibody engineering and viral surveillance techniques. Invivyd's lead product candidate, adintrevimab, is a neutralizing antibody undergoing clinical trials for both treatment and prevention of coronavirus disease. Additionally, the company is developing monoclonal antibody candidates, including VYD222 and VYD224, aimed at offering neutralizing protection against SARS-CoV-2, alongside discovery stage candidates for seasonal influenza prevention. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the Nasdaq.
Key slides for Invivyd Inc


Q1 2025
Invivyd Inc


Q2 2025
Invivyd Inc
Latest articles
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
Ticker symbol
IVVD
Country
🇺🇸 United States